JP2020528457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528457A5 JP2020528457A5 JP2020526666A JP2020526666A JP2020528457A5 JP 2020528457 A5 JP2020528457 A5 JP 2020528457A5 JP 2020526666 A JP2020526666 A JP 2020526666A JP 2020526666 A JP2020526666 A JP 2020526666A JP 2020528457 A5 JP2020528457 A5 JP 2020528457A5
- Authority
- JP
- Japan
- Prior art keywords
- endostatin
- composition
- chemotherapeutic agent
- cancer
- dna double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710638033.2 | 2017-07-30 | ||
| CN201710638033 | 2017-07-30 | ||
| CN201710733900 | 2017-08-24 | ||
| CN201710733900.0 | 2017-08-24 | ||
| PCT/CN2018/097609 WO2019024814A1 (zh) | 2017-07-30 | 2018-07-27 | 抑制dna依赖蛋白激酶催化亚基的药物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528457A JP2020528457A (ja) | 2020-09-24 |
| JP2020528457A5 true JP2020528457A5 (https=) | 2021-09-09 |
| JP7492687B2 JP7492687B2 (ja) | 2024-05-30 |
Family
ID=65233426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526666A Active JP7492687B2 (ja) | 2017-07-30 | 2018-07-27 | Ｄｎａ－ｐｋｃｓを阻害するための薬物治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200237796A1 (https=) |
| EP (1) | EP3662922B1 (https=) |
| JP (1) | JP7492687B2 (https=) |
| CN (1) | CN110913884B (https=) |
| AU (1) | AU2018310410B2 (https=) |
| CA (1) | CA3103035A1 (https=) |
| WO (1) | WO2019024814A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762615B2 (en) | 1998-06-15 | 2003-07-03 | Arch Development Corporation | Combination of radiotherapy and anti-angiogenic factors |
| CA2332179C (en) | 1998-06-30 | 2011-06-28 | Sloan-Kettering Institute For Cancer Research | Uses of dna-pk |
| US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
| US7078485B2 (en) | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
| CN1891717A (zh) * | 2005-07-08 | 2007-01-10 | 南京大学 | 内皮抑素的化学修饰方法及其应用 |
| CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| CN102698270B (zh) | 2011-03-28 | 2016-02-03 | 清华大学 | 一种增强靶细胞摄取治疗剂的方法和药物组合物 |
| CN108291248B (zh) | 2011-09-09 | 2024-03-08 | 清华大学 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
-
2018
- 2018-07-27 EP EP18840639.1A patent/EP3662922B1/en active Active
- 2018-07-27 AU AU2018310410A patent/AU2018310410B2/en active Active
- 2018-07-27 WO PCT/CN2018/097609 patent/WO2019024814A1/zh not_active Ceased
- 2018-07-27 CA CA3103035A patent/CA3103035A1/en active Pending
- 2018-07-27 JP JP2020526666A patent/JP7492687B2/ja active Active
- 2018-07-27 US US16/635,006 patent/US20200237796A1/en not_active Abandoned
- 2018-07-27 CN CN201880046593.1A patent/CN110913884B/zh active Active
-
2023
- 2023-11-17 US US18/512,519 patent/US20240165140A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11034733B2 (en) | Flagellin compositions and uses | |
| Michael et al. | Nanotechnology for treatment of glioblastoma multiforme | |
| Koga et al. | Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts | |
| ES2764396T3 (es) | Vector de ARN bicatenario dirigido a EGFR para tratamiento sistémico del cáncer | |
| ES2368963A1 (es) | Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado. | |
| US7470667B2 (en) | Methods of treating cancer using a modified endostatin protein | |
| Zhang et al. | Hyaluronate-based self-stabilized nanoparticles for immunosuppression reversion and immunochemotherapy in osteosarcoma treatment | |
| Lin et al. | Role of spinal CXCL1 (GROα) in opioid tolerance: a human-to-rodent translational study | |
| JP2022527412A (ja) | がんの治療にセネカバレーウイルス（ｓｖｖ）を使用する組成物および方法 | |
| Xia et al. | Nanobody engineered and photosensitiser loaded bacterial outer membrane vesicles potentiate antitumour immunity and immunotherapy | |
| US20190031732A1 (en) | Compositions and methods for treating cancers | |
| Zhou et al. | De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy | |
| Hunt | Precision targeting of intraperitoneal tumors with peptideguided nanocarriers | |
| Cereda et al. | Pancreatic cancer: failures and hopes—a review of new promising treatment approaches | |
| ES2854298T3 (es) | Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1 | |
| JP2026001029A (ja) | がん治療のための化学療法剤とα－ラクトアルブミン－オレイン酸複合体の組合せ | |
| WO2016014899A1 (en) | Flagellin derivatives and uses | |
| WO2019168921A1 (en) | Plectin-targeted liposomes/parp inhibitor in the treatment of cancer | |
| JP2020528457A5 (https=) | ||
| CA3191866A1 (en) | Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment | |
| JP2023527209A5 (https=) | ||
| Hsieh et al. | Ctni-50. a Randomized Phase 2 Trial of Cediranib/Olaparib versus Bevacizumab in Patients with Recurrent glioblastoma: Updated Results | |
| Lepland | Precision targeting of tumour-associated macrophages in triple negative breast cancer | |
| Mali et al. | EVALUATION OF IN VITRO CYTOTOXIC POTENTIAL OF DIFFERENT CARMUSTINE FORMULATIONS AGAINST U-87 MG HUMAN GLIOBLASTOMA CELL LINE. | |
| KR102137391B1 (ko) | 암 치료를 위한 Colicin D 단편의 용도 |